Health Business Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Health Business Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Alexion Pharmaceuticals, Inc.
New England Journal of Medicine Publishes Case Reports on the Investigational Use of Soliris® eculizumab in Patients with Atypical Hemolytic Uremic Syndrome aHUS
February 13th, 2009
Two separate case reports published in the New England Journal of Medicine (NEJM) examine the investigational use of Soliris ® (eculizumab), a terminal complement inhibitor developed by Alexion Pharmaceuticals, Inc. (Nasdaq: ALXN), in patients with a rare and severe inflammatory disease called atypical Hemolytic Uremic Syndrome (aHUS). In both cases, physicians observed a significant reduction in the destruction of red blood cells, reduced platelet consumption and improved kidney function following Soliris therapy. Separately, Alexion announced that it is currently initiating clinical trials of eculizumab in patients with aHUS. Soliris is approved in the United States,...
Source: Health Business Week (2009-02-13)
|
